Bright Green Partners with Benuvia for Raw Material Supply
Bright Green Partners with Benuvia Operations
Bright Green Corporation (Nasdaq: BGXX) has announced a significant partnership through a letter of intent to supply its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a recognized leader in pharmaceutical cannabinoids. This collaboration emphasizes the commitment and capability of Bright Green to provide high-quality organic materials to U.S. pharmaceutical entities.
Homegrown Supply Agreement
This homegrown agreement showcases Bright Green’s ability to meet the demand for quality raw materials within the pharmaceutical industry. Under this supply deal, Benuvia plans to utilize Bright Green’s unique position to manufacture Schedule I & II raw materials while adhering strictly to Good Agricultural and Collection Practices (GACP), Good Manufacturing Practices (GMP), and DEA regulations, all completely within the United States. Such compliance ensures the production of domestically sourced cGMP, pharmaceutical-grade Active Pharmaceutical Ingredients (APIs), aimed at both U.S. and global markets.
Strategic Growth for Bright Green
With this partnership, Bright Green reinforces its strategy to emerge as the leading supplier of plant-based raw materials for the production of cannabinoid, psychedelic, and opioid-related drugs in the United States. The Company is also in the midst of a new fundraising round and forming additional supply agreements, positioning it for significant performance impacts in the forthcoming year.
DEA Compliance and Future Operations
The recent completion of the Drug Enforcement Administration (DEA) annual operational procedures for Schedule I & II drug cultivation and manufacturing marks a pivotal moment for Bright Green, as it positions the company favorably to start operations. Meeting these high national standards is instrumental in Bright Green’s journey to supply essential materials to the pharmaceutical sector, further aiding innovation within the industry.
About Bright Green Corporation
Bright Green is among the select companies authorized by the U.S. government and the New Mexico Board of Pharmacy to cultivate, manufacture, and legally sell Schedule I and II plant-derived drugs for research, pharmaceutical applications, and associated exports. The Company’s approval from the U.S. Drug Enforcement Administration supports its vision to enhance the quality of life through the opportunities provided by cannabis and other plant-based therapies.
About Benuvia Operations, LLC
Benuvia Operations, LLC is at the forefront of the pharmaceutical industry, leading in the research, development, and commercialization of innovative pharmaceutical products across various therapeutic domains. Their commitment to patient outcomes is reflected in their stringent scientific methodologies and quality manufacturing practices. With FDA registration, DEA licensing, and cGMP certification, Benuvia is positioned as a trusted entity. Their flagship product, SYNDROS, is an FDA-approved medication aimed at managing anorexia-related weight loss in AIDS patients and mitigating chemotherapy-induced nausea and vomiting.
Media Inquiries & Investor Relations Contact
For media inquiries or investor relations, please contact: ir@brightgreen.us
Frequently Asked Questions
What is the significance of the partnership between Bright Green and Benuvia?
This partnership allows Bright Green to supply high-quality raw materials needed by Benuvia for pharmaceutical applications, particularly in cannabinoid and psychedelic sectors.
How does Bright Green ensure compliance with regulations?
Bright Green adheres to Good Agricultural and Collection Practices (GACP), Good Manufacturing Practices (GMP), and DEA regulations in its operations to ensure compliance.
What is Bright Green's vision for the future?
Bright Green aims to become the leading domestic supplier of plant-based raw materials for the pharmaceutical industry, enhancing the quality of life through innovative therapies.
What products does Benuvia specialize in?
Benuvia focuses on developing pharmaceutical products that address various therapeutic needs, including their flagship product SYNDROS for assisting patients with anorexia and chemotherapy side effects.
How can interested parties learn more about Bright Green?
Individuals can visit www.brightgreen.us for more information about Bright Green Corporation and its initiatives.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.